MEK inhibition remodels the immune landscape of mutant KRAS tumors to overcome resistance to PARP and immune checkpoint inhibitors

Mutant KRAS tumors are associated with poor outcomes at least in part due to decreased therapeutic sensitivity. Here we show that KRAS mutations are associated with resistance to monotherapy and combination therapy with Poly-(ADP-ribose) polymerase inhibitors (PARPi) and immune checkpoint blockade w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res
Hlavní autoři: Yang, Bin, Li, Xi, Fu, Yu, Guo, Ensong, Ye, Youqiong, Li, Fuxia, Liu, Si, Xiao, Rourou, Liu, Chen, Lu, Funian, Huang, Jia, Qin, Tianyu, Han, Leng, Peng, Guang, Mills, Gordon B., Sun, Chaoyang, Chen, Gang
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265237/
https://ncbi.nlm.nih.gov/pubmed/33589518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2370
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky